SynAct Pharma AB (“SynAct”) (Nasdaq Stockholm: SYNACT), a clinical-stage biotechnology company focused on resolving inflammation through selective activation of the melanocortin system, held a Capital Markets Day on Monday, September 23, 10:00-13:00 CEST at GT30, Grev Turegatan 30 in Stockholm.
Agenda
10:00 Introduction and corporate update – Jeppe Øvlesen, CEO
10:15 SynAct strategy and direction – Anders Kronborg, Chairman of the Board
10:25 Resolution therapy – Novel approach to the clinical management of inflammatory diseases – Prof. Mauro Perretti
10:45 Current and Future Treatments of Early Rheumatoid Arthritis and the Medical Need – Asger Reinstrup Bihlet, CSO at Sanos Group
11:05 Q&A session
11:25 Break
11:40 Resomelagon program and ADVANCE study – Thomas Jonassen, CSO
12:05 Emerging Clinical profile in newly-diagnosed RA patients – the business case – Jim Knight, CBO
12:30 Sector and market overview – Sten Scheibye, Member of the Board
12:40 Q&A session
12:55 Wrap-up and summary – Jeppe Øvlesen, CEO
13:00 Reception and lunch